Heteroaryl substituted nicotinamide compounds

US9169252B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Joseph B. Santella · Springfield, US
• Sreekantha Ratna Kumar · Bengaluru, IN
• John V. Duncia · Newtown, US
• Daniel S. Gardner · Furlong, US
• Venkatram Reddy Paidi · Bengaluru, IN
• Satheesh Kesavan Nair · Kanchinakote, IN
• John Hynes · Washington Crossing, US
• Hong Wu · Meekrap-oord, CN
• Natesan Murugesan · Lawrenceville, US
• Kandhasamy Sarkunam · Hosur, IN
• Piramanayagam Arunachalam · Bengaluru, IN

Key dates

• Filing date: Jan 2, 2015
• Grant date: Oct 27, 2015
• Expiry date: Jan 2, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/65616
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are compounds of Formula (I)or salts thereof, wherein: HET is a heteroaryl selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, imidazo[4,5-b]pyridinyl, and purinyl, wherein said heteroaryl is substituted with Ra and Rb; and R1 and R2 are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.